Fig. 7: Redox metabolic phenotype of CD34+ AML cells in coculture with vehicle (PBS) or EVAML.
Percentages of CD34+ cells isolated from AML patients at diagnosis in coculture with vehicle (PBS) (n = 14) or EVAML (n = 24) for 24 h before staining for a ROS/MITO: ROShi MITOlo, ROShi MITOhi, ROSlo MITOhi, and ROSlo MITOlo subsets; b ROS/GSH to determine the ROShi GSHlo (p = 0.0006), ROShi GSHhi (p = 0.02), ROSlo GSHhi, and ROSlo GSHlo subsets; c GSH/MITO: GSHhi MITOlo, GSHhi MITOhi (p = 0.004), GSHlo MITOhi (p = 0.01), and GSHlo MITOlo subsets. Significant differences were reported as (*) p < 0.05, (**) p < 0.01, (***) p < 0.001 using the Mann–Whitney test for unpaired samples from 14 biological experiments. d The expression levels for ROS (n = 14; p = 0.02), MITO (n = 12; p = 0.02), and GSH (n = 13) in CD34+ cells treated with EVAML are expressed as MFI normalized to the MFI of untreated cells used as a control (MFI fold change). Significant differences were reported as (*) p < 0.05 using the Mann–Whitney test for unpaired samples. e Percentages of ROShi MITOhi (p < 0.0001 and p = 0.0004) and ROSlo MITOhi (p = 0.0007 and p = 0.01) for CD34+ AML cells treated with favorable EVAML (n = 9), intermediate EVAML (n = 7) or adverse EVAML (n = 8) from 10 independent experiments. Two-way ANOVA reported significant differences with Šidák’s multiple comparisons test. P values < 0.01 (**), <0.001 (***), <0.0001 (****) were considered significant. f gMFI for ThiolTracker of AML CD34+ cells treated for 24 h with vehicle (PBS), RSL3 (1 µM; p = 0.02), EVAML (p = 0.0003) or after pre-treatment with RSL3 (1 µM) for 6 h before adding EVAML (p = 0.0004 versus EVAML). The expression levels for each marker are expressed as gMFI normalized to the MFI of untreated cells used as a control (MFI fold change). One-way ANOVA with Tukey’s multiple comparisons (n = 7). P values < 0.05 (*) and <0.01 (**) were considered significant. Data are presented as mean values ± SEM. Source data are provided as a Source Data file.
